Climate change is one of several drivers of recurrent outbreaks and geographical range expansion of zoonotic infectious diseases in Europe. Policy and decision-makers need tailored monitoring of climate-induced disease risk, and decision-support tools for timely early warning and impact assessment for proactive preparedness and timely responses. The abundance of open data in Europe allows the establishment of more effective, accessible, and cost-beneficial prevention and control responses. IDAlert will co-create novel policy-relevant pan-European indicators that track past, present, and future climate-induced disease risk across hazard, exposure, and vulnerability domains at the animal, human and environment interface. Indicators will be sub-national, and disaggregated through an inequality lens. We will generate tools to assess cost-benefit of climate change adaptation and mitigation measures across sectors and scales, to reveal novel policy entry points and opportunities. Surveillance, early warning and response systems will be co-created and prototyped to increase health system resilience at regional and local levels, and explicitly reduce socio-economic inequality. Indicators and tools will be co-produced through multilevel engagement, innovative methodologies, existing and new data streams and citizen science, taking advantage of intelligence generated from selected hotspots in Spain, Greece, The Netherlands, Sweden, and Bangladesh that are experiencing rapid urban transformation and heterogeneous climate-induced disease threats. For implementation, IDAlert has assembled European authorities in climate modelling, infectious disease epidemiology, social sciences, environmental economics, One Health and EcoHealth. Further, by engaging critical stakeholders from the start, IDAlert will ensure long-lasting impacts on EU climate policy, and provide new evidence and tools for the European Green Deal to strengthen population health resilience to climate change.

Mental illnesses represent a huge burden for society, the economy, and the aMental illnesses represent a huge burden for society, the economy, and the affected individuals. To significantly increase citizens? mental health, today?s symptom-based diagnoses need to be complemented by biological criteria accounting for individual and sex differences. Furthermore, early detection and prevention measures need to be improved. RE-MEND addresses the current gaps and challenges with an interdisciplinary approach by: i) focussing on four critical life stages in which an individual?s susceptibility to mental illness is strongly influenced by changes in endocrine signalling, including sex hormones, namely early life, puberty, peripartum, and transition into old age; ii) integrating data from large population-based longitudinal cohort studies allowing for discovery of risk and protective factors as well as biological patterns that influence mental states in the general population across these life stages; iii) complementing epidemiological with experimental studies to establish correlative and causative links leading to mechanistic understanding; iv) using advanced biostatistics as well as machine learning and artificial intelligence for data integration and biomarker and drug target discovery; v) combining the biological approaches with communication science studies to efficiently translate its results to societal impact. Ultemately, RE-MEND will result in: i) Significantly increased mental health literacy among stakeholders and citizens; ii) Validated biomarkers for assessing mental health state and its predisposition as well as more accurate diagnoses and personalised preventive and therapeutic measures; iii) Recommendations for early detection, better prevention, and drug design strategies to protect vulnerable individuals from mental illness in sensitive life stages; and iv) strategies on how these advances can be used to decrease stigma and increase prevention behaviour.

The proposed Prevention and Screening Innovation Project towards Elimination of Cervical Cancer (PRESCRIP-TEC) will lead to effective and innovative cervical cancer screening, including direct treatment and follow-up for women in resource-poor or hard-to-reach settings in the world, by improving availability, accessibility, acceptability and quality of services. PRESCRIP-TEC will conduct implementation research into cervical cancer screening and secondary prevention in different settings in four countries over three continents: Bangladesh and India in Asia, Uganda in Africa, and Slovakia in Eastern Europe. We will analyse patient- and health services-related facilitators and barriers for uptake of cervical cancer screening in low- and middle-income countries and in vulnerable groups in Eastern Europe. By taking existing screening protocols in the four countries, we will introduce 1) interactive information with communities via mobile devices and social media; 2) client-friendly, community-based strategies, with self-test for high risk HPV infection; and 3) artificial intelligence in gynaecological examination. The use of artificial intelligence built into mobile devices offers a future for high quality diagnostics in resource-poor settings. By doing so, we will reduce the number of physical examinations and implement screenings by lower-level trained cadres. In addition, through a cost-effectiveness analysis and a business case for the global introduction of hrHPV testing as routine screening for cervical cancer, we will show the advantage of point-of-delivery testing and the benefits of self-testing for cancer in the post-COVID era, which reduces pressure on the health system. PRESCRIP-TEC will strengthen evidence of innovative strategies for cervical cancer screening as advocated by the World Health Organization and will contribute to eradication of cervical cancer worldwide through prevention and early diagnosis, alleviating the global burden of cancer.

PUREMIND will deliver the first Integrated Mental Healthcare Ecosystem (IMHE) to predict/early identify Mental Health Disorders (MHD) and create more optimal personalised interventions to prevent MHD and thereby improving wellbeing in children, adolescents, and young adults (0–25 years). The ecosystem will mitigate key challenges associated with MHDs, specifically 1)Detection: 1 in 7 undetected and untreated MHD cases, 2)Efficiency of treatment: lack of tools and guidelines for personalised multidisciplinary interventions that work, 3)Access to Support and Care: long waiting times for care due to lack of trained personnel, 4)Inequality: disparate and inadequate inter- and intra-country mental healthcare services and 5)Modern Cultures and Lifestyle: the increasingly recognised risk factor of digital addiction resulting in sedentary, socially isolated lifestyle contributing to MHD. These will be addressed by PUREMIND’s approach of combining analytical modelling of dynamical systems in the cyber-physical context of a subject’s personal natural environment-gene-gut-brain-MHD interactions process creating a much-needed personalised intervention synthesis framework that will be exploited by an AI engine to deliver optimised personalised intervention, and a unique digital twin educating young people how MHD might develop depending on their environment and lifestyle. These 2 components will be combined in an accessible/ adaptable mobile app MyMind to measure at scale and allow a subject to seamlessly access a 4-tier service architecture involving family, community, clinical and emergency services, to support prediction/early detection of MHD, empowering them to monitor their own mental health at home/educational/community settings and taking preventive actions against MHD. The IMHE will be designed using Implementation Science approach and will be validated in a 12month pilot study in 7 European countries and 2 LMICs covering different socioeconomic and cultural scenarios.

It has become apparent that the ease of travelling, global warming, and changes in the environment accelerate the spread of infectious diseases of zoonotic origin. International collaboration is essential to impact on the control of disease epidemics, and as the COVID pandemic has shown rapid diagnostics are one of the main pillars. PREPARE-TID will target infectious agents of three types: an ongoing neglected epidemic, an ongoing emerging epidemic, and an ongoing elimination drive. The aim is to develop the necessary in vitro diagnostic tools for preparedness needed in case of the emergence of infectious agent X. PREAPRE-TID is a multidisciplinary research consortium drawn from 16 European and 3 international research organisations and SMEs. Biomedical researchers will work alongside epidemiologists, clinicians, veterinarians, and software engineers to implement a pipeline from a mobile suitcase sequencing laboratory with a simple bioinformatics to a fieldable rapid nucleic acid extraction procedure, a mobile smartphone linked molecular point-of-care and a multiplex PCR one-health surveillance platform, and a one health digital platform. These will provide innovative diagnostic solutions for cross-border health threats at international level. PREPARE-TID will increase the accessibility to novel diagnostics for detection of pathogens with pandemic potential. The consortium will deliver point-of-care and mobile diagnostics, which can be easily deployed and mass produced in case of an epidemic or pandemic.